

Fabrizio Accardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6097727/publications.pdf>

Version: 2024-02-01

25
papers

619
citations

687363
13
h-index

713466
21
g-index

25
all docs

25
docs citations

25
times ranked

1235
citing authors

#	ARTICLE	IF	CITATIONS
1	Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. <i>Blood</i> , 2016, 128, 667-679.	1.4	128
2	Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. <i>BioMed Research International</i> , 2015, 2015, 1-13.	1.9	87
3	Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20. <i>Leukemia</i> , 2016, 30, 409-416.	7.2	55
4	The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 815-827.	2.8	52
5	Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. <i>Oncotarget</i> , 2017, 8, 56598-56611.	1.8	52
6	The osteoblastic niche in the context of multiple myeloma. <i>Annals of the New York Academy of Sciences</i> , 2015, 1335, 45-62.	3.8	49
7	IL21R ⁺ expressing CD14 ⁺ CD16 ⁺ monocytes expand in multiple myeloma patients leading to increased osteoclasts. <i>Haematologica</i> , 2017, 102, 773-784.	3.5	36
8	Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. <i>Oncotarget</i> , 2017, 8, 53053-53067.	1.8	27
9	Novel targets for the treatment of relapsing multiple myeloma. <i>Expert Review of Hematology</i> , 2019, 12, 481-496.	2.2	25
10	Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients. <i>Cancers</i> , 2019, 11, 321.	3.7	24
11	The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 231-234.	3.4	18
12	The Proteasome and Myeloma-Associated Bone Disease. <i>Calcified Tissue International</i> , 2018, 102, 210-226.	3.1	15
13	Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?. <i>International Journal of Hematology</i> , 2017, 105, 104-108.	1.6	14
14	Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3022.	2.4	12
15	The transcriptomic profile of CD138 ⁺ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged. <i>Haematologica</i> , 2019, 104, e465-e469.	3.5	8
16	Bone marrow Dkk1 levels are a new independent risk factor for progression in patients with smoldering myeloma. <i>British Journal of Haematology</i> , 2018, 183, 812-815.	2.5	5
17	A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.4	5
18	Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1238-1241.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients. Blood, 2016, 128, 4647-4647.	1.4	2
20	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood, 2016, 128, 5697-5697.	1.4	2
21	Neurofibromatosis type I and multiple myeloma coexistence: A possible link?. Hematology Reports, 2018, 10, 7457.	0.8	1
22	The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4. Blood, 2015, 126, 5315-5315.	1.4	0
23	Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively. Blood, 2016, 128, 4464-4464.	1.4	0
24	Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients. Blood, 2018, 132, 3183-3183.	1.4	0
25	Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass. Blood, 2019, 134, 1795-1795.	1.4	0